Compact Trip Representation over Networks

The final publication is available at Springer via http://dx.doi.org/10.1007/978-3-319-46049-9_23[Abstract] We present a new Compact Trip Representation ( CTRCTR ) that allows us to manage users’ trips (moving objects) over networks. These could be public transportation networks (buses, subway, trains, and so on) where nodes are stations or stops, or road networks where nodes are intersections. CTRCTR represents the sequences of nodes and time instants in users’ trips. The spatial component is handled with a data structure based on the well-known Compressed Suffix Array ( CSACSA ), which provides both a compact representation and interesting indexing capabilities. We also represent the temporal component of the trips, that is, the time instants when users visit nodes in their trips. We create a sequence with these time instants, which are then self-indexed with a balanced Wavelet Matrix ( WMWM ). This gives us the ability to solve range-interval queries efficiently. We show how CTRCTR can solve relevant spatial and spatio-temporal queries over large sets of trajectories. Finally, we also provide experimental results to show the space requirements and query efficiency of CTRCTR .Ministerio de Economía y Competitividad; TIN2013-46238-C4-3-RMinisterio de Economía y Competitividad; TIN2013-47090-C3-3-PMinisterio de Economía y Competitividad; IDI-20141259Ministerio de Economía y Competitividad; ITC-20151305Ministerio de Economía y Competitividad; ITC-20151247Xunta de Galicia; GRC2013/053Chile.Fondo Nacional de Desarrollo Científico y Tecnológico; 1140428Chile. Instituto de Sistemas Complejos de Ingeniería ; FBO 1

Biological performance of a promising Kefiran-biopolymer with potential in regenerative medicine applications: a comparative study with hyaluronic acid

Kefiran from kefir grains, an exopolysaccharide (EPS) produced by lactic acid bacteria (LAB), has received an increasing interest because of its safe status. This natural biopolymer is a water-soluble glucogalactan with probed health-promoting properties. However, its biological performance has yet to be completely recognized and properly exploited. This research was carried out to evaluate the in vitro antioxidant and the in vitro anti-inflammatory properties of Kefiran biopolymer. Regarding antioxidant activity, the results demonstrated that the Kefiran extract possessed the strongest reducing power and superoxide radical scavenging, over hyaluronic acid (HA, gold standard viscosupplementation treatment). This exopolysaccharide showed a distinct antioxidant performance in the majority of in vitro working mechanisms of antioxidant activity comparing to HA. Moreover, Kefiran presented an interesting capacity to scavenge nitric oxide radical comparing to the gold standard that did not present any potency. Finally, the cytotoxic effects of Kefiran extracts on hASCs were also performed and demonstrated no cytotoxic response, ability to improve cellular function of hASCs. This study demonstrated that Kefiran represented a great scavenger for reactive oxygen and nitrogen species and showed also that it could be an excellent candidate to promote tissue repair and regeneration.Hajer Radhouani, Cristiana Gonçalves and F. Raquel Maia were supported by grants with reference SFRH/BPD/100957/2014, SFRH/BPD/94277/2013 and SFRH/BPD/117492/2016, respectively of Fundação para a Ciência e a Tecnologia (FCT) from Portugal. JM Oliveira also would like to thank FCT for the fund provided under the program Investigador FCT 2015 (IF/01285/2015).info:eu-repo/semantics/publishedVersio

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)